The FDA’s unapproved drug initiative has had an impact on catheter lock therapy for home infusion patients. Patients who require a central venous access device (CVAD) are at a significant risk for catheter-associated bloodstream infections. The lack of options and high cost have created an urgent need in the U.S. for FDA-approved central line catheter lock solutions.
In this white paper learn about:
- Challenges and costs of Ethanol Lock Therapy (ELT)
- Need for FDA-approved alternative lock solutions
Related healthcare insights
Video
Our infusion care ecosystem is based on a commitment to clinical innovation and providing consistent, convenient and compassionate care.
Article
Our eco-friendly, fully sustainable prescription packaging eliminates polystyrene and reduces CO2, water and plastic waste.
Article
Optum tackles the many issues infusion pharmacy care faces as it serves vulnerable patients with acute needs and complex conditions.